Rapid Micro Biosystems grew Q3 2026 revenue 21.6% to $9.5 million with a record 25.2% gross margin, and agreed to be acquired by Merck KGaA, Darmstadt, Germany. It withdrew 2026 guidance.
Ticker: RPID
Rapid Micro Biosystems (RPID), which makes automated microbial quality control systems for pharmaceutical manufacturing, reported results for the quarter ended September 30, 2026 on November 16. Both its Product and Service businesses grew, and margins widened. On the same day the company announced a definitive agreement to be acquired by Merck KGaA (MKGAY), Darmstadt, Germany.
The key numbers (third quarter 2026)
Metric | This year | Last year | Change |
|---|---|---|---|
Total revenue | $9.5 million | $7.8 million | +21.6% |
Product revenue | $6.5 million | $5.2 million | +24.9% |
Service revenue | $3.0 million | $2.6 million | +14.9% |
Recurring revenue | $5.2 million | $4.8 million | +6.9% |
Gross margin | 25.2% | 8.9% | |
Total operating expenses | $13.0 million | $12.1 million | +8.1% |
Net loss | $11.3 million | $11.5 million | |
Net loss per share | $0.23 | $0.26 | |
Adjusted EBITDA loss | $7.9 million | $9.4 million |
The company placed seven new Growth Direct systems and completed 12 customer validations, compared with five placements and four validations a year earlier. Product gross margin rose 19 percentage points to 12%, and Service gross margin rose 14 percentage points to 54%. Operating expenses included a $0.7 million restructuring charge tied to an efficiency program announced in August. General and administrative expenses rose 12.2% and sales and marketing expenses rose 4.3%, while research and development expenses fell 15.8%. Total cost of revenue was $7.1 million in both periods.
Acquisition and reporting
Because of the acquisition announcement, Rapid Micro Biosystems said it will not host a conference call and is withdrawing its full year 2026 guidance. It will also delay filing its Form 10-Q for the quarter, and intends to file within the extension period permitted under Rule 12b-25. Cash, cash equivalents and short-term investments were approximately $7 million at September 30, 2026.
President and CEO Rob Spignesi said joining the Life Science business of Merck KGaA would significantly expand the reach of the Growth Direct platform.
Nine months so far
For the nine months ended September 30, 2026, total revenue was $25,584 thousand against $22,305 thousand, and the net loss was $38,466 thousand against $34,626 thousand.
Source: SEC Form 8-K Exhibit 99.1
Comments
Log in or sign up to join the conversation.